Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Epoetin alfa - Kyowa Kirin-Amgen

Drug Profile

Epoetin alfa - Kyowa Kirin-Amgen

Alternative Names: Epoetin - Amgen; Epoetin-α; Epogen; Epoimmun; Eprex; Erypo; Espo; Kirin EPO; KRN-5702; Li Xue Bao; Procrit; r-HuEPO; recombinant human EPO; recombinant human erythropoietin

Latest Information Update: 16 Jul 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Kirin-Amgen
  • Developer Janssen Biotech; Janssen-Cilag; Johnson & Johnson; Kyowa Kirin; Weihai Sinogen Pharmaceutical
  • Class Antianaemics; Recombinant erythropoietins
  • Mechanism of Action Erythropoiesis stimulants; Erythropoietin receptor agonists; Stem cell stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Anaemia
  • No development reported Neurological disorders; Stroke

Most Recent Events

  • 05 Dec 2017 Efficacy and safery data from the phase III EPO-ANE-3010 trial in Anaemia presented at the 40th Annual San Antonio Breast Cancer Symposium (SABCS-2017)
  • 24 Mar 2017 Agence Nationale de Sécurité du Médicament et des Produits de Santé approves epoetin alfa for symptomatic Anaemia in adult patients with primary myelodysplastic syndromes in France
  • 13 Jun 2016 Efficacy and adverse events data from a phase III trial in Anaemia presented at the 21st Annual Congress of the European Hematology Association (EHA-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top